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Cancer Research UK Beatson Institute, Glasgow, United Kingdoma; Department of Biology, University of York, York, United Kingdomb
Inflammation in the tumor microenvironment has many tumor-promoting effects. In particular, tumor-associated macrophages
(TAMs) produce many cytokines which can support tumor growth by promoting survival of malignant cells, angiogenesis, and
metastasis. Enhanced cytokine production by TAMs is tightly coupled with protein synthesis. In turn, translation of proteins
depends on tRNAs, short abundant transcripts that are made by RNA polymerase III (Pol III). Here, we connect these facts by
showing that stimulation of mouse macrophages with lipopolysaccharides (LPS) from the bacterial cell wall causes transcrip-
tional upregulation of tRNA genes. The transcription factor NF-B is a key transcription factor mediating inflammatory signals,
and we report that LPS treatment causes an increased association of the NF-B subunit p65 with tRNA genes. In addition, we
show that p65 can directly associate with the Pol III transcription factor TFIIIB and that overexpression of p65 induces Pol III-
dependent transcription. As a consequence of these effects, we show that inhibition of Pol III activity in macrophages restrains
cytokine secretion and suppresses phagocytosis, two key functional characteristics of these cells. These findings therefore iden-
tify a radical new function for Pol III in the regulation of macrophage function which may be important for the immune re-
sponses associated with both normal andmalignant cells.
Chronic inflammation caused by microbial infection, autoim-mune diseases, or other pathologies increases the risk of tu-
morigenesis. Failure to clear the infection during chronic inflam-
mation is a major source of tissue damage. During this process,
reactive oxygen species lead to DNA damage and mutation (1).
Furthermore, to sustain tissue homeostasis, cells continuously
proliferate, and this can be a major driving force for the initial
transformation of tumor cells (2). Tumor-infiltrating immune
cells produce cytokines that activate transcription factors (e.g.,
nuclear factorB [NF-B], STAT3, or AP-1) in premalignant cells
to control numerous protumorigenic processes, including sur-
vival, proliferation, angiogenesis, and invasion (3).
Macrophages are professional phagocytic cells of the innate
immune system. They are a major line of host defense, being re-
sponsible for pathogen killing and for triggering inflammation. In
addition, macrophages are also responsible for maintaining tissue
homeostasis and repair, mainly through extracellular matrix re-
modeling and scavenging apoptotic cells and cellular debris (4).
Microenvironmental cues can polarizemacrophages to exhibit
either proinflammatory (M1, classically activated macrophages)
or anti-inflammatory (M2, alternatively activated macrophages)
phenotypes. Classically activated macrophages secrete a large va-
riety of factors, including interleukins, chemokines, interferons,
reactive oxygen species, and complement components (5).
Growing evidence indicates that macrophages present in tu-
mors (called tumor-associated macrophages [TAMs]), instead of
being effective in host defense, actually contribute to cancer pro-
gression by stimulating cancer cell proliferation, angiogenesis,
metastasis, and suppression of adaptive immunity. Given the im-
portant role of macrophages in tumor promotion, TAMs are con-
sidered a potential target for anticancer therapy (6).
NF-B is a key transcription factor mediating inflammatory
signals and has also been suggested to have a role in tumor pro-
gression (7). There are five members of the NF-B family of tran-
scription factors: RelA (p65), RelB, c-Rel, NF-B1 (p50/p105),
and NF-B2 (p52/p100). NF-B may consist of many possible
homo- and heterodimers; however, p50/RelA heterodimers are
most commonly observed (8). In resting cells, NF-B is bound
(and kept in the cytoplasm) by IB proteins (IB, IB, and
IBε). Following an inflammatory stimulus, IB is phosphory-
lated and undergoes proteasomal degradation, which leads to lib-
eration of NF-B and its translocation to the nucleus, where it
activates target genes. The kinase responsible for the phosphory-
lation of IB is the IB kinase (IKK) complex, which consists of
two kinases (IKK and IKK) and a regulatory subunit, NEMO/
IKK (reviewed in reference 9). NF-B regulates the transcription
of a wide variety of target genes, including inflammation-related
genes (e.g., those encoding cytokines and chemokines,Cox-2, and
those encoding tumor necrosis factor alpha [TNF-]) (10).
NF-B is activated by a variety of inflammatory stimuli, such as
interleukin 1 (IL-1) and TNF-, and inhibited by IL-10 and non-
steroidal anti-inflammatory drugs (9, 11, 12). Moreover, aberrant
NF-B activity is frequently involved in diseases, and the function
of RelA is altered in many cancers (13).
RNA polymerase III (Pol III) is responsible for the synthesis of
many noncoding RNAs involved in protein biosynthesis and the
maturation of other RNAmolecules (14). Inmammalian cells, Pol
III transcription is directly activated by c-Myc and extracellular
signal-regulated kinase (ERK) and repressed byRB, p53, andMaf1
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(15, 16). Deregulation of Pol III transcription has been implicated
in a variety of human diseases. In particular, elevated Pol III ac-
tivity is a recurring feature of mouse and human tumors (14).
Interestingly, NF-B subunit RelA/p65 has been shown to associ-
ate with Pol III-transcribed genes in human lymphoblastoid cells
(17). However, its role in Pol III transcriptional regulation has not
yet been determined.
In this study, we show that stimulation of macrophages with
the bacterial cell wall component lipopolysaccharides (LPS) up-
regulates transcription of tRNA genes. This effect occurs concom-
itantly with an increased association of p65 with tRNA genes, and
we show that direct activation of the NF-B pathway induces Pol
III-dependent transcription.Ultimately andmost importantly, we
also show that inhibition of Pol III activity severely compromises
macrophage function by delaying phagocytosis and restraining
cytokine secretion, underscoring a novel and critical role for Pol
III activity in the innate immune response in these cells.
MATERIALS AND METHODS
Cell culture. Cells were cultured in a humidified incubator with 5% CO2
at 37°C. Murine leukemia virus transformed macrophages RAW264.7
and human U2OS cells (ATCC) were grown in DMEM supplemented
with 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 U/ml),
and 10% fetal bovine serum (FBS), unless otherwise stated. THP-1 and
murine bone marrow-derived macrophages were grown in RPMI 1640
supplemented with 2mM L-glutamine, penicillin (100 U/ml), streptomy-
cin (100 U/ml), and 10% FBS, unless otherwise stated. When indicated,
cells were treated with LPS (Sigma) at 1g/ml, mouse recombinant mac-
rophage colony-stimulating factor (M-CSF) (MACS Miltenyi Biotec) at
10 ng/ml, RNA polymerase III inhibitor ML-60218 (Merck) at 100 M,
phorbol-12-myristate-13-acetate (PMA) (Sigma) at 5 ng/ml, andCPI-203
(Cambridge Bioscience) at 10 M.
THP-1 cell differentiation. THP-1 monocytes were differentiated
with PMA essentially as described previously (18). Briefly, one million
cells were plated in 6-cm dishes in 3mlmedium containing 5 ng/ml PMA.
Upon incubation of THP-1 monocytes with PMA, the cells become ad-
herent to culture dishes. After 48 h, dishes were washed twice with phos-
phate-buffered saline (PBS) to remove nonadherent cells. Then, medium
was replaced with fresh RPMI 1640 with supplements except PMA. After
another 48 h, cells were used for experiments.
Bone marrow-derived macrophages (BMDM). Wild-type male and
female mice of a mixed genetic background were sacrificed at 3 to 6
months of age with CO2 and subsequent cervical dislocation. Bone mar-
row was flushed from femurs and tibias with RPMI 1640 medium using a
5-ml syringe and a 23-gauge needle. Cells were passed through a cell
strainer, spun, resuspended inRPMI 1640medium supplementedwith 10
ng/mlM-CSF, and plated on 10-cmnon-tissue culture sterile petri dishes.
After 72 h, dishes were washedwith PBS to remove nonadherent cells, and
fresh RPMI 1640 medium supplemented with 10 ng/ml M-CSF was
added. Forty-eight hours later, dishes were washed with PBS, and cells
were flushed off the culture dish with 7 ml RPMI 1640 medium supple-
mented with 10 ng/ml M-CSF using a 10-ml syringe and a 23-gauge nee-
dle. Cells were counted and plated on 6-well (phagocytosis) or 12-well
(enzyme-linked immunosorbent assay [ELISA] andRNA isolation) tissue
culture plates. After another 24 h, cells were used for experiments.
Detection of de novo protein synthesis. Levels of newly synthesized
protein were estimated using a nonisotopic labeling method as described
previously (19), with a Click-it HPG Alexa Fluor 488 protein synthesis
assay kit (Life Technologies). Briefly, primary bonemarrow-derivedmac-
rophages were grown for 30 min in RPMI 1640 medium without methi-
onine (Life Technologies) and supplementedwith 50ML-homopropar-
gylglycine (HPG). Then, cells were washed with ice-cold PBS, harvested,
and fixed with 50% methanol. The subsequent steps were performed ac-
cording to themanufacturer’s instructions. Labeled cells were subjected to
flow cytometry on a FACSCalibur instrument (BD Biosciences) and ana-
lyzed with the Cell Quest Pro software. Data are represented as percent-
ages of total fluorescent signal relative to the signal of the nontreated
sample (NT), which was set to 100%.
Phagocytosis assay. Fluorescent latex beads 2 m in diameter (Life
Technologies) were preopsonized by 10 dilution in macrophage me-
dium (RPMI 1640 with all supplements) for 1 h at 4°C. Beads were added
to macrophage culture plates in 10:1 ratio (beads to cells) and incubated
for 3 h. Plates were then placed on ice, and macrophages were washed
twice with ice-cold PBS and scraped into 0.25 ml PBS using a cell scraper.
Cells were then subjected to flow cytometry. A control sample without
fluorescent beads was used to assess the autofluorescence of cells.
Transfections. U2OS cells were plated in 6-well plates at a density of
7.5  104 per well. Cells were transfected using Lipofectamine 2000 ac-
cording to the manufacturer’s recommendations. A 250-ng amount of
each plasmid was used per well. pRSV, pRSV-p65, pRSV-p65(RHD), and
pCMV-p50 were kindly provided by Neil Perkins (Institute for Cell and
Molecular Biosciences, Newcastle University). For Brf1 knockdown,
murine primary bone marrow-derived macrophages were transfected
with 20 nM small interfering RNA (siRNA) oligonucleotides using
Lipofectamine 2000. Transfections were done six times with 1-day
intervals after every two transfections. The treatment experiments
were performed on the day following the last transfection. The siRNAs
used were Brf1 ON-TARGETplus SMARTpool (L-046566-01; Dhar-
macon) and AllStars negative-control siRNA (1027280; Qiagen).
Construction of stable RAW264 cell lines. Stable RAW264 cell lines
were generated by retroviral transduction. Ecotropic HEK293 packaging
cells were transfected with retroviral pBabe-EMPTY vector, pBabe vector
encoding a mutant version (A32/36) of IB, or pBabe vector encoding
enhanced green fluorescent protein (EGFP)-tagged Brf1. RAW264 cells
were infected three times using HEK293 conditionedmedium and subse-
quently selected in medium containing puromycin at 2 g/ml until there
were no live cells on the control plate (usually 6 to 7 days). Pools of cells
were used for experiments.
Protein extracts and Western blotting. Cells were washed with ice-
cold PBS and harvested by scraping directly into microextraction buffer
(450 mM NaCl, 20 mM HEPES [pH 7.9], 0.2 mM EDTA, 25% glycerol,
0.5% Triton X-100). Extracts were sonicated for 30 s in Bioruptor (Diag-
enode) with maximum energy setting and spun for 10 min at 14,000 g
at 4°C. Supernatants were collected, and protein concentration was as-
sessed using Bio-Rad protein assay. Proteins were precipitated from a
volume of extract corresponding to 30g proteinwith an equal volume of
10% trichloroacetic acid (TCA). Samples were spun for 10 min at
14,000 g at 4°C, and the pellet was washed with cold acetone, dried, and
resuspended in Laemmli buffer (pH 8.8), followed by incubation for 15
min at 55°C with shaking. A 15-g amount of protein was resolved on a
4-to-20% gradient gel (Bio-Rad), transferred to a nitrocellulose mem-
brane, and incubated with antibodies in 5%milk in Tris-buffered saline–
Tween (TBST). Antibodies to the following proteins were used: p65 (SC-
392/SC-109; for Rel homology domain [RHD] Western blotting), p50
(SC-7178), IB (SC-847), actin (SC-1615), and c-Myc (SC-764; Santa
Cruz Biotechnology); TBP (ab818), hemagglutinin (HA) tag (ab1424),
andGFP tag (ab290; Abcam); andBrf1 (A301-228A; Bethyl Laboratories).
RNA isolation and cDNA synthesis. Total RNA was isolated from
cells using TRIzol (Life Technologies) according to the manufacturer’s
instructions. Fifty nanograms of RNA was used for cDNA synthesis using
a QuantiTect reverse transcriptase kit (Qiagen). To increase the efficiency
of tRNAs’ cDNA synthesis, oligonucleotides specific to the 3= end of tRNA
were added to the reaction mixture, each at the final concentration 0.6
M. The oligonucleotides sequences are listed in Table S1 in the supple-
mental material.
ChIP. For each time point, one 15-cm culture dish of cells at around
80% percent confluence was used. Cell cross-linking was done by adding
37% formaldehyde to a final concentration of 1% for 8 min at room
temperature, followed by the addition of glycine to a final concentration
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of 125 mM. Cells were lysed in 0.5 ml chromatin immunoprecipitation
(ChIP) buffer (150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5%
NP-40, 0.5% SDS, 1 mM sodium butyrate, 50 mM Tris-HCl [pH 8.0])
containing 1.5 protease and phosphatase inhibitor cocktail (Thermo
Scientific). The lysate was sonicated 6 times for 15 s with 30-s intervals in
a Diagenode Bioruptor set to maximum power. For each IP, 125 l of
extract was used, and 50 l of extract was used as input. For IPs, extract
was diluted five times with ChIP buffer with no SDS, and 3 g of p65
(SC-372) antibody was added. Following overnight incubation at 4°C
with rotation, 50 l of protein G magnetic beads (Dynal Life Technolo-
gies) was added, and the mixtures were further incubated for 6 h. Beads
were washed once with ChIP buffer (no SDS), twice with high-salt buffer
(600 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 50 mM
Tris-HCl [pH 8.0]), twice with LiCl buffer (250 mM LiCl, 1 mM EDTA,
0.5% sodium deoxycholate, 0.5%NP-40, 10mMTris-HCl [pH 8.0]), one
more time with ChIP buffer (no SDS), and once with final wash buffer
(0.1%NP-40, 10 mMTris-HCl [pH 7.5]). All the washes were performed
on a rotating wheel at room temperature for 4 min. DNA recovery and
purification were performed using Chelex 100 resin (Bio-Rad), as de-
scribed previously (20).
Quantitative PCR. Quantitative PCR was performed on a Bio-Rad
CFX 96 unit using a 3-min incubation at 95°C, followed by 40 cycles of 20
s at 95°C, 30 s at 57°C, and 30 s at 72°C (with a plate read after each cycle).
Amelting curve analysis was performed for each sample after PCR ampli-
fication to ensure that a single product with the expected melting curve
characteristics was obtained. Each sample was loaded in triplicate. Each
plate contained cDNA dilutions for the standard curve, a non-reverse
transcriptase control, and a nontemplate control. PCR efficiencies were
between 90% and 100%. The primer sequences used are described in
Table S2 in the supplemental material. Data were processed in Bio-Rad
CFX Manager 3.0 and then analyzed in Excel (Microsoft). Data are ex-
pressed in arbitrary units calculated from standard curve where the high-
est cDNA concentration was set to 1.
Coimmunoprecipitation. U2OS cells were transfected with EGFP-
Brf1 andHA-p65 and harvested after 48 h. Total protein was isolated with
extraction buffer (30 mM Tris-HCl [pH 8], 150 mM NaCl, 1% Triton
X-100, 1% Igepal CA-630, 10% glycerol) and mechanical disruption by
freezing and thawing cells three times. After insoluble debris had been
spun down, extracts were diluted twice with dilution buffer (30 mMTris-
HCl [pH 8], 150 mM, 10% glycerol) to bring the concentration of Triton
and Igepal to 0.5%.All buffers were supplementedwith complete protease
inhibitor cocktail (Roche). Protein concentration was estimated by Brad-
ford assay. A suspension ofDynabeads (proteinGmagnetic beads) (50l;
Invitrogen) was washed twice with 0.5 ml PBS containing 0.5% bovine
serum albumin (BSA), and then 5 l antibody against GFP (ab290; Ab-
cam) and 1.25 l of normal rabbit IgG (X0903; Dako) were added and
incubated for 6 h. After that time, beads were washed with IP buffer (30
mM Tris-HCl [pH 8], 150 mM NaCl, 0.5% Triton X-100, 0.5% Igepal
CA-630, 10% glycerol), and 250 g of protein extract was added and
incubated overnight with rotation at 4°C. For coimmunoprecipitation
experiments using RAW264 cells stably expressing EGFP-Brf1, 750 g of
protein extract was incubated overnight with 5 g of either antibody
against HA tag (ab1424; Abcam) or GFP tag (A11120; Life Technologies).
Then, 50 l of a suspension of Dynabeads was added, and extracts were
incubated for another 6 h. Following 3 washes with IP buffer, immuno-
precipitated proteins were eluted by boiling for 3 min in the SDS gel
electrophoresis loading buffer and analyzed by SDS-PAGE followed by
Western blotting.
ELISA. Supernatants from the macrophage treatment experiments
were collected, the volumewasmeasured, and cytokine concentrationwas
estimated using inflammatory cytokine multianalyte ELISA or custom
ELISA (IL-6, IL-10, and TNF-) kits from Qiagen (MEM-004A and
CMEM-0608A, respectively). Samples were treated as described in the
manufacturer’s instructions. Samples for TNF- detection were diluted
twice in macrophage RPMI 1640 medium. The optical density (OD) val-
ueswere corrected for the volume of themediumharvested and total RNA
content in the cells. To reduce the variation between replicates, the largest
amount of cytokine within a replicate was set to 100%.
Statistics. P values were calculated using a paired Student t test or a
ratio Student t test in situations where data were presented as fold change.
All the calculations were performed in Excel (Microsoft). If no statistical
value is shown, there was no significant difference between data sets.
RESULTS
LPS stimulates protein synthesis and tRNA expression in mac-
rophages. LPS is a major component of the outer membranes of
most Gram-negative bacteria and is a strong proinflammatory
mediator, potently activating immune system cells (21). LPS treat-
ment leads to activation ofmultiple signaling pathways, including
NF-B, interferon regulatory factor 3 (IRF3), andmembers of the
mitogen-activated protein kinase (MAPK) family (ERK/c-Jun N-
terminal kinase [JNK]/p38) (22). LPS triggers cell cycle arrest (23–
25) and together with interferon gamma (IFN-) polarizes mac-
rophages toward an M1 phenotype (classically activated
macrophages). M1 macrophages secrete high levels of proinflam-
matory cytokines (such as IL-1, TNF-, and IL-6) and exhibit
antibacterial capacity (3).
It has been shown previously that the activation of macro-
phages is associated with dynamic changes in transcriptional and
protein synthesis profiles (26). The authors of that study showed
that almost five thousand different proteins are newly synthesized
upon LPS treatment in RAW264 macrophages. Other studies re-
ported a 20% increase in total protein content in murine primary
bone marrow-derived macrophages after 27 h of treatment with
LPS (27) and also de novo protein synthesis after 22 h of treatment
with LPS, as measured by radioactive leucine incorporation (25).
Because the reported experiments were performedwith quite long
LPS exposure times, we were interested to see whether the re-
sponse is more rapid. To test this, we monitored incorporation of
the amino acid analog L-homopropargylglycine (HPG) into newly
synthesized proteins in primary murine bone marrow-derived
macrophages treated with LPS for 1, 2, 3, and 5 h. As shown in Fig.
1, the LPS treatment induced a gradual increase of HPG incorpo-
ration. After 3 and 5 h of LPS treatment, the rate of protein syn-
thesis was about 80% higher than the rate in nontreated control
cells. This confirms the published observations and also shows
FIG 1 LPS treatment enhances de novo protein synthesis in macrophages.
Mouse primary bonemarrow-derivedmacrophages were treatedwith 1g/ml
LPS for the indicated periods of time. The medium was replaced with methi-
onine-free medium containing the methionine analogue HPG, and cells were
incubated for 30 min. Cells were harvested and subjected to flow cytometry to
assess HPG incorporation. The value for the NT sample was set to 100%. The
experiment was performed onmacrophages derived from three different mice
(n 3). Error bars represent standard errors of the means (SEM).
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that de novo protein synthesis is rapidly induced within hours of
LPS treatment.
Since Pol III products, such as tRNAs, are crucial for transla-
tion and a rapid increase in protein synthesis is associated with
LPS treatment, we sought to determine whether Pol III activity is
also upregulated in response to LPS. To test this, RAW264 mac-
rophages were treated with LPS for 1, 2, 3, 5, and 8 h. Cells were
harvested and total RNA was isolated. Reverse transcription-
quantitative PCR (RT-qPCR) analysis revealed that upon LPS
treatment, tRNATyr and tRNAIle levels increase, reaching a peak at
5 h (Fig. 2A). The response is more pronounced if RAW264 mac-
rophages are deprived of serum for 16 h before LPS addition (see
Fig. S1 in the supplemental material). Similar effects were ob-
served in primary murine bone marrow-derived macrophages
and human acute monocytic leukemia THP-1 cells, which had
been differentiated into macrophages (dTHP-1). RT-qPCR anal-
ysis revealed that tRNATyr and tRNAIle levels are upregulated in
bonemarrow-derivedmacrophages treated with LPS for 5 and 8 h
(Fig. 2B) and in dTHP-1 cells treated with LPS for 6 h (Fig. 2C).
These collective data show that tRNA expression is upregulated
by LPS.
NF-B is involved in the regulation of Pol III activity by LPS.
Because of its key role in responses to inflammatory stimuli, we
investigated whether NF-B is involved in regulation of Pol III
activity upon LPS treatment. To test this, we took advantage of the
fact that inhibition of the IKK kinase complex blocks activation of
NF-B by preventing its nuclear localization (9). RAW264 mac-
rophages and THP-1 cells differentiated into macrophages were
therefore pretreated for 1 hwith IKK inhibitor PS1145 or dimethyl
sulfoxide (DMSO) as a control and then treated with LPS for 5 or
6 h, respectively. Cells were harvested, and total RNAwas isolated.
As a marker of NF-B activity, we examined IB (NFKBIA)
mRNA levels, which are highly responsive to changes in NF-B
activity (28, 29). As shown in Fig. 3A and B, IKK inhibitor PS1145
reduced the upregulation of IB mRNA after LPS treatment in
both RAW264 and dTHP-1 cells, proving the effectiveness of
the IKK inhibitor. Similarly, after LPS treatment the Pol III prod-
uct tRNATyr was upregulated in DMSO-treated RAW264 and
dTHP-1 cells (Fig. 3A and B). However, IKK inhibition signifi-
cantly reduced this LPS-induced upregulation of tRNATyr.
To further assess the role of NF-B in Pol III regulation, we
constructed aRAW264 cell line stably expressing amutant formof
NF-B repressor IB. This phosphorylation-defective IB
(S32A/S36A), called a superrepressor, is resistant to degradation
and thus continuously sequesters NF-B in the cytoplasm, pre-
venting its activation (30, 31). As shown in Fig. 3C, expression of
the superrepressor IB partially prevented the activation of its
own gene (NFKBIA) upon LPS treatment. Superrepressor IB
also significantly reduced LPS-induced upregulation of tRNATyr
(Fig. 3C). Moreover, the same effect was observed in serum-de-
prived RAW264 macrophages (see Fig. S2 in the supplemental
material). Overall, these data show that the NF-B pathway is
involved in regulation of Pol III activity in response to LPS.
p65 binds to tRNA genes. The NF-B family of transcription
factors consists of five proteins, namely, RelA (p65), RelB, c-Rel,
NF-B1 (p50/p105), and NF-B2 (p52/p100) (13). Kasowski and
colleagues performed chromatin precipitation followed by deep
sequencing to look at genome-wide binding of p65 protein in
human lymphoblastoid cells (17). We took advantage of these
data and manually inspected the presence of p65 on tRNA genes
using the ENCODE transcription factor ChIP track in the UCSC
genome browser (http://genome.ucsc.edu) (32, 33). This revealed
that p65 is present at many Pol III-transcribed genes, including
tRNAs, 7SL RNA, 7SK RNA, and RMRP (RNase MRP) genes. As
shown in Fig. S3 in the supplemental material, p65 binding peaks
overlap tRNA genes and Pol III peaks. The ChIP sequencing
(ChIP-seq) data revealed that in GM12878 lymphoblastoid cells,
p65 is present at 151 out of a total 631 tRNA genes in the hg18
human genome compilation (see Fig. S4 in the supplemental ma-
terial).
We also looked at overlap between p65 binding and Pol III
binding in three cell lines from which four sets of ChIP-seq data
were available for Pol III, that is, the GM12878, K562 (two anti-
bodies against different subunits, RPC155 and RPC32) and
HeLa-S3 cell lines (see Fig. S4 in the supplemental material). It
should be clearly noted here that none of those data are straight-
forwardly comparable, since p65 data are from cells treated with
TNF- and Pol III data are from untreated cells. However, it is
noteworthy that in all four data sets, p65 binding overlaps Pol III
FIG 2 LPS upregulates RNA polymerase III activity. Mouse RAW264 macro-
phages (A), murine primary bone marrow-derived macrophages (BMDM)
(B), and human THP-1 cells differentiated into macrophages (dTHP-1) (C)
were treatedwith 1g/ml LPS and harvested at the indicated time points. RNA
was isolated fromcells and transcript levels of the indicated geneswere assessed
using RT-qPCR. RNA levels were normalized to GAPDH (A and B) or RPLP0
mRNA (C), and the value for the zero time point or the NT (nontreated) cells
was set to 1. An asterisk indicates a P value of	0.05. Error bars represent SEM.
The experiments were performed three times each in duplicate (A), five times
(B), and four times (C).
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binding. This suggests that p65 may preferentially bind to tRNA
genes that are already occupied by Pol III. A minority of p65-
positive, Pol III-negative tRNA genes also appear in this compar-
ison, but this should be viewed with caution, as the actual Pol III
binding is likely to be different upon TNF- treatment.
Given our finding that Pol III targets are upregulated upon LPS
treatment in an IKK-dependent manner, we sought to determine
whether LPS treatment induces p65 binding to tRNA genes in
mousemacrophages. To test this, RAW264 cells were treated with
LPS for 1, 2, and 3 h prior to analysis by ChIP assay. Under these
conditions, p65 protein showed time-dependent binding to the
promoter of its known target gene NFKBIA and also to tRNATyr
and tRNAIle genes (Fig. 4). In all cases, the binding peak occurred
after 1 h of LPS treatment. The p65 binding efficiency to tRNA
genes was much lower than its binding to the NFKBIA promoter
(
1% versus 
7% IP/input, respectively). This is probably be-
cause p65 binds directly to its DNA motif in the NFKBIA pro-
moter, whereas p65 may be recruited to tRNA genes by protein/
protein interactions, rather than binding DNA directly (see
below).
The response is not limited to LPS stimulus, as we could see
similar effects in RAW264 macrophages treated with TNF- (see
Fig. S5A in the supplemental material). Moreover, TNF- up-
regulated tRNA gene transcription in murine primary bone mar-
row-derived macrophages (see Fig. S5B in the supplemental ma-
terial). Overall, these data suggest a direct role of p65 in regulating
tRNA expression.
Overexpression of p65 activates several Pol III-transcribed
genes. To further investigate the role of NF-B in Pol III activa-
tion, we overexpressed its p65 and p50 subunits. U2OS cells were
transfectedwith plasmids encoding p65 or p50 or empty vectors as
controls. At 24 h posttransfection, cells were serum deprived
(0.2% FBS) for another 24 h and then harvested.Western blotting
revealed that overexpression of p65 led to increased levels of the
knownNF-B targets (28, 34, 35) IB and p50 (Fig. 5A), whereas
overexpression of p50 had no effect on IB levels. Importantly,
we also found that overexpression of p65 also increased the levels
of tRNATyr, tRNAThr, tRNAIle, and 7SL RNA (Fig. 5B). Overex-
pression of p50 had no effect on IB, p65, or Pol III activity,
suggesting that p65 is a limiting factor and p50 may be in relative
excess in these cells.
p65 belongs to the family of Rel proteins, characterized by the
FIG 3 Inhibition of the NF-B pathway partially precludes Pol III activation
upon LPS treatment. Mouse RAW264 macrophages (A) and human THP-1
cells differentiated into macrophages (dTHP-1) (B) were pretreated for 1 h
with 10MIKK inhibitor PS1145 or with DMSO (0.2%) as a control and then
treated with 1g/ml LPS for 5 (RAW264) or 6 (dTHP-1) hours. (C) RAW264
control cells or cells stably expressing the superrepressor IkB were treated with
1 g/ml LPS for 5 h. RNA was isolated from cells, and transcript levels of the
indicated genes were assessed using RT-qPCR. RNA levels were normalized to
GAPDH mRNA (A and C) or RPLP0 mRNA (B), and the value for DMSO-
treated or NT (nontreated) cells was set to 1. Error bars represent SEM (n 4
[A and C] or n 3 [B]).
FIG 4 p65 binds tRNA genes upon LPS treatment. Mouse RAW264 macro-
phages were treated with 1 g/ml LPS and harvested at the indicated time
points. p65 binding to theNFKBIA promoter, the gene desert (GD), and tRNA
genes was assessed by ChIP assay followed by RT-qPCR. Error bars represent
SEM (n 3).
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presence of a Rel homology domain (RHD). Additionally, p65,
c-Rel, and RelB proteins also contain transactivation domains
(TAD), which are required for activation of NF-B target genes
(7).Wewere interested to knowwhether this TAD is also required
for activation of Pol III-transcribed genes. To test this, U2OS cells
were transfected with either empty plasmid or plasmids encoding
full-length p65 or a truncated version of p65, containing only the
Rel homology domain. At 24 h posttransfection, cells were serum
deprived (0.2% FBS) for another 24 h and then harvested. As
shown byWestern blotting (Fig. 5C), we were able to overexpress
both full-length p65 and the truncated version containing only the
RHD. Although overexpression of p65 increased tRNA and 7SL
RNA levels, the truncated version did not, despite its robust ex-
pression (Fig. 5D). These results show that the TAD required for
activation of Pol II-transcribed p65 target genes is also necessary
for stimulating Pol III activity.
It has been shown that c-myc is an NF-B target gene (36), and
we consistently observed increased levels of c-Myc in cells overex-
pressing p65 (see Fig. S6A in the supplemental material). More-
over, c-Myc is known to positively regulate Pol III activity (37). It
was possible, therefore, that the effect of p65 overexpression on
Pol III activity is indirect andmediated by c-Myc. To examine this
possibility, we transfected U2OS cell with either a plasmid encod-
ing p65 or empty vector as a control. At 24 h posttransfection, cells
were serumdeprived (0.2%FBS), cultured for 24 h, andharvested.
At 6 h before harvesting, cells were treated with 10MCPI-203, a
potent bromodomain-containing protein (BET) inhibitor which
inhibits c-myc transcription (38). As expected, inhibitor treat-
ment decreased both c-myc transcript and protein levels (see Fig.
S6A and B in the supplemental material). Although c-myc induc-
tion was blocked, the Pol III products tRNATyr and 7SL RNAwere
still induced by p65 (see Fig. S6B in the supplemental material).
This indicates that c-Myc is not required for p65-dependent up-
regulation of Pol III activity, and these data further support the
direct role of p65 in Pol III activation.
p65 associates with TFIIIB. Transcription of tRNA genes re-
quires transcription factor TFIIIB, comprising subunits TBP,
Bdp1, and Brf1 (39). Brf1 protein belongs to the family of TFIIB-
related transcription factors, which are characterized by the pres-
ence of a zinc ribbon domain and two internal cyclin repeats (39).
TFIIB and TBP have independently been shown to interact with
p65. Moreover, the transactivation domain of p65 and one of the
cyclin repeat domains of TFIIB were crucial for this interaction
(40, 41). Since Brf1 is homologous to TFIIB, we askedwhether p65
is able to associate with Brf1. In order to test this, U2OS cells were
cotransfected with plasmids encoding EGFP-tagged Brf1 andHA-
tagged p65. Protein extracts were then prepared, coimmunopre-
cipitated, and analyzed by Western blotting. This revealed that
Brf1 was associated with TBP protein, a known Brf1 binding part-
ner. Furthermore, we also found that p65 protein coimmunopre-
cipitated with Brf1 (Fig. 6A).
To assess whether endogenous p65 in macrophages is able to
interact with TFIIIB, we generated a RAW264 cell line stably ex-
pressing EGFP-tagged Brf1. The cells were treated with LPS for 1
FIG 5 Overexpression of NF-B subunit p65 increases tRNA expression. U2OS cells were transfected with empty vectors and/or vectors encoding p65 or p50,
as indicated. After 24 h, cells were serum deprived (0.2% FBS), cultured for another 24 h, and harvested. (A)Western blot analysis of p65, p50, IB, and actin.
(B) RT-qPCR analysis of indicated Pol III transcripts (n 3). (C and D) Transactivation domain of p65 is necessary for upregulation of Pol III activity. U2OS
cells were transfected with empty vector or vector encoding full-length p65 or truncated version of p65 containing only the Rel homology domain (RHD). After
24 h, cells were serum deprived (0.2% FBS), cultured for another 24 h, and harvested. (C) Western blot analysis of p65 and tubulin. (D) RT-qPCR analysis to
monitor levels of the indicated Pol III transcripts (n 2). RNA levels were normalized toRPLP0mRNA, and the value for empty vector sampleswas set to 1. Error
bars represent SEM.
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and 2 h, and protein extracts were prepared, coimmunoprecipi-
tated, and analyzed by Western blotting. As shown in Fig. 6B, we
could again see the association of TBP with Brf1 in both treated
and untreated cells. Furthermore, we could also see that LPS in-
duced association of p65 with Brf1. These data indicate that p65
can associate with TFIIIB through interactions with its compo-
nents Brf1 and/or TBP.
Pol III inhibition restrains cytokine secretion by primary
macrophages. Macrophages are one of the principal cell types
involved in innate immune responses. Upon treatment with
LPS, macrophages secrete a large variety of cytokines, including
TNF-, IL-6, and IL-10 (42), which modulate the immune re-
sponse. We were therefore interested to know whether inhibition
of Pol III affects cytokine secretion by macrophages. To test this,
bone marrow-derived macrophages were pretreated with DMSO
or the Pol III inhibitor ML-60218 for 6 h. Macrophages were then
treated with 1 g/ml LPS for 5 h and 8 h. Cells and culture me-
dium were collected for RNA extraction and ELISA analysis, re-
spectively. As shown in Fig. 7A, RT-qPCR analysis revealed that
after 5 or 8 h of LPS treatment, tRNATyr and tRNAIle levels were
upregulated, and this response was diminished in the cells treated
Pol III inhibitor. Furthermore, ELISA analysis revealed that
TNF-, IL-6, and IL-10 were secreted into the medium upon LPS
treatment (Fig. 7B). Reducing Pol III activity significantly de-
creased levels of secreted IL-6 and IL-10 but had amild or no effect
on TNF-. As shown in Fig. 7C, TNF-, IL-6, and IL-10 mRNA
levels were upregulated upon LPS treatment, which is consistent
with the previously published data (43–45).Moreover, after 8 h of
LPS treatment, all three transcript levels were lower than those in
corresponding samples at 5 h of treatment, which suggests that at
the time points tested, the cellular response to LPSwas decreasing.
Pol III inhibition had no effect on TNF- mRNA levels, whereas
IL-6 mRNA levels were modestly elevated (Fig. 7C). The effect of
Pol III inhibition on secretion of these cytokines can therefore not
be explained by changes in their mRNA expression. In contrast,
IL-10mRNA expression showed amarkedly different pattern: Pol
III inhibition resulted in lower IL-10mRNA levels than inDMSO-
treated cells at both time points tested (Fig. 7C). The changes in
IL-10 mRNA expression most likely reflect indirect effects of Pol
III inhibition.
To further assess the impact of abolishing Pol III activity on
cytokine secretion, we knocked down Brf1 in bone marrow-de-
rived macrophages using RNA interference. The effectiveness of
Brf1 depletion is shown by the Western blots in Fig. 8A. Macro-
phages were treated with 1g/ml LPS for 2.5 h or 5 h. As shown in
Fig. 8B, Brf1 knockdown efficiently abolished LPS-induced up-
regulation of tRNATyr and tRNAIle. ELISA analysis revealed that,
similar to the ML-60218 inhibitor, Brf1 knockdown significantly
decreased levels of secreted IL-6 and IL-10 but had no or amodest
effect on TNF- (Fig. 8C). Abolishing Pol III activity by Brf1
knockdown had a minor or no effect on TNF- and IL-6 mRNA
levels, respectively. IL-10 mRNA levels were consistently lower
than those in control cells after LPS treatment, although after 5 h
of treatment, the values did not reach statistical significance (Fig.
8D). Altogether, these data suggest that Pol III activity is required
for efficient cytokine secretion by macrophages. Moreover, given
the similarities between the effects of Brf1 knockdown and the
inhibitor ML-60218, the results also confirm the specificity of the
latter.
Pol III inhibition impairs phagocytosis by macrophages.
Phagocytosis is one of the primary functions of macrophages (4).
Because Pol III inhibition affects cytokine secretion, another im-
portant macrophage function, we were interested to know if Pol
III activity is also required for phagocytosis.
In order to test this, first we used THP-1 cells differentiated
into macrophages (dTHP-1), which were treated with DMSO
(0.2%) or the Pol III inhibitor ML-60218 (100 M) for 4 h. The
efficacy of the inhibitor was confirmed by RT-qPCR, which re-
vealed a 2-fold decrease in tRNATyr and 4-fold decrease in tRNAIle
expression after normalization to RPLP0mRNA (see Fig. S7 in the
supplemental material). Serum-opsonized fluorescent beads were
then added, and after 3 h, cells were harvested and analyzed by
flow cytometry.
Phagocytic capacity was assessed by estimating the total num-
ber of cells that engulfed at least one bead, by measuring total
mean fluorescence of engulfed beads, and also by estimating the
number of cells that engulfed one, two, three, four or more beads.
As shown in Fig. 9A, approximately 70% of both nontreated and
DMSO-treated dTHP-1 cells engulfed at least one bead. However,
upon Pol III inhibitor treatment, phagocytosis was markedly re-
duced, with only 40% of cells having engulfed at least one bead.
Moreover, we could also see a difference in the number of en-
gulfed beads, asmeasured by the total fluorescent signal generated
by those cells. As shown in Fig. 9B, the total fluorescence signal
FIG 6 p65 interacts with TFIIIB. (A) U2OS cells were transfected with EGFP-Brf1 and HA-p65 and harvested after 48 h. (B) RAW264 cells stably expressing
EGFP-tagged Brf1were treated with 1 g/ml LPS for the indicated periods of time. Cellular extracts were incubated with magnetic beads coated with rabbit
anti-GFP antibody or normal rabbit IgG as a control (A) or with mouse anti-GFP or mouse anti-HA antibody as a control (B). After extensive washes,
immunoprecipitated proteins were eluted and analyzed by Western blotting with antibodies against GFP, HA tag, and TBP (A) or Brf1, p65, and TBP (B).
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was reduced by 40% upon Pol III inhibition. These results sug-
gested that phagocytosis is generally impaired in cells treated with
Pol III inhibitor. The biggest difference was in the population of
cells that engulfed four or more beads (Fig. 9C). The lower the
number of engulfed beads, the smaller was the difference between
Pol III inhibitor-treated and control cells, suggesting that the for-
mer cells are still able to engulf beads, although at a lower rate.
Thus, partial Pol III inhibition restricts phagocytosis but does not
block it completely.
We also performed the same experiments using primary murine
bone marrow-derived macrophages (BMDM). As LPS treatment
stimulates phagocytosis in primary macrophages (27), we tested
whether Pol III inhibition affects LPS-induced phagocytosis.
BMDM were treated with DMSO (0.2%) or the Pol III inhibi-
tor ML-60218 for 4 h. One hour later, cells were also treated with
1 g/ml LPS. Serum-opsonized fluorescent beads were then
added, and after 3 h, cells were harvested and analyzed by flow
cytometry. Similar to dTHP-1 cells, BMDM showed a reduced
capacity to engulf opsonized beads upon Pol III inhibition (Fig.
9D to F). There were 10% fewer cells that had engulfed at least one
bead (Fig. 9D) and a 20% reduction in the total fluorescent signal
generated by engulfed beads (Fig. 9E) compared toDMSO-treated
cells. As for dTHP-1 cells, the greatest effect of the Pol III inhibitor
was on the number of cells engulfing four or more beads. More-
over, as reported previously (27), LPS induced the rate of phago-
cytosis in macrophages (Fig. 9E to G). We did not see much dif-
ference in the number of cells that engulfed at least one bead
compared to non-LPS samples, which may be explained by the
fact that the engulfment rate was already high, reaching 90% of all
cells. On the other hand, we did see an almost 20% increase in the
total fluorescent signal, suggesting that LPS indeed increased the
number of engulfed beads. Importantly, this increase was partially
blocked by the inhibition of Pol III (Fig. 9E). These results show
that Pol III activity is important for efficient phagocytosis in
dTHP-1 cells and primary bone marrow-derived macrophages.
DISCUSSION
The study presented here demonstrates that activation of innate
immune responses in mouse macrophages causes upregulation of
transcription by RNA polymerase III. We show that the NF-B
pathway is involved in this process, since its inhibition precludes
Pol III upregulation. Furthermore, overexpression of the NF-B
subunit p65 activates Pol III transcription. In macrophages
treated with LPS, p65 binds to tRNA genes, which may allow di-
rect interaction with the Pol III transcription apparatus. We also
provide evidence that inhibition of RNA polymerase III activity
FIG 7 Inhibition of RNA polymerase III activity restrains cytokine secretion bymouse bonemarrow-derivedmacrophages. Bonemarrow-derivedmacrophages
were pretreatedwithDMSO (0.2%) or 100MRNApolymerase III inhibitorML-60218 for 6 h, and then cells were stimulatedwith 1g/ml LPS for the indicated
times. Cells and culture medium were harvested for RNA extraction and ELISA analysis, respectively. (A) RT-qPCR measurements of the levels of indicated
tRNAs. RNA levels were normalized to GAPDH mRNA, and the value for the nontreated (NT) sample was set to 1. (B) Levels of the indicated interleukins
secreted into the culture medium, as determined by ELISA. Results are expressed as corrected OD values as described in Materials and Methods. (C) RT-qPCR
measurements of mRNA levels of the indicated interleukins, shown as fold change relative to GAPDHmRNA levels. Error bars represent SEM (n 3).
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abolishes the major macrophage functions of phagocytosis and
cytokine secretion.
Macrophages have many biological functions, such as antigen
presentation, target cell cytotoxicity, phagocytosis, tissue remod-
eling, and regulation of inflammation. They play an essential role
in frontline defense, leading to the killing ofmicroorganisms, par-
asites, and tumor cells (reviewed in reference 4). Activated mac-
rophages (e.g., by LPS or IFN-) secrete a large amount of prod-
ucts, including enzymes, complement components, reactive
oxygen intermediates, coagulation factors, cytokines, nitrite, and
various other substances (46). All these compounds contribute to
the microbicidal, cytotoxic (tumoricidal), or fungicidal potential
of macrophages (47). Such a vast repertoire of products synthe-
sized by macrophages requires efficient protein synthesis, which
in turn tightly depends on RNA polymerase III products such as
tRNAs. Indeed, our data show that concomitantly with increased
de novo protein synthesis, tRNAs are upregulated during activa-
tion of macrophages by LPS.
The decreased cytokine secretion after Pol III inhibition could
be partially explained by the reduced efficiency of the translation
machinery. However, since secretion of TNF-was onlymodestly
affected by inhibition of Pol III activity, it is unlikely that the effect
is the result of a general defect in protein synthesis. Pol III may
influence some later stage of signal propagation that is initiated by
TNF- or IL-6 secreted into themedium. IL-10 gene transcription
is primarily regulated by NF-B (48), but it has also been shown
that expression of this cytokine is regulated by IL-6 in a STAT3-
dependent manner (49). It is possible therefore that a defect in
IL-6 secretion abolishes IL-10 synthesis at the transcription level.
Since we have shown that IL-6mRNA levels are not changed upon
Pol III inhibition, regulation appears to be posttranscriptional.
Secretion is probably not impeded, as IL-6 and TNF- use the
same secretory pathway (50). However, previous studies have
shown that IL-6 levels can be regulated posttranscriptionally by 3=
untranslated region (UTR)-driven mRNA decay (51). Additional
control at the translational level has not been excluded.
The most striking effect of Pol III inhibition in macrophages is
the reduced phagocytosis. It is widely appreciated that phagocy-
tosis is a complex process which involves multiple stages, such as
particle recognition, internalization, maturation and transport of
phagosomes, and fusion of the phagosomes with lysosomes (52,
53). Each of these steps is highly regulated, thus creating the pos-
sibility of multiple points being affected by Pol III inhibition. Elu-
cidation of the role of Pol III in phagocytosis is undoubtedly in-
teresting but is beyond the scope of this work and requires
extensive further investigation.
FIG 8 Brf1 knockdown reduces cytokine secretion by mouse bone marrow-derived macrophages. Bone marrow-derived macrophages were transfected with a
siRNA pool targeting Brf1 or nontargeting negative (Neg) siRNA. Cells were stimulated with 1g/ml LPS for the indicated time. Cells and culture mediumwere
harvested for protein and RNA extraction and ELISA analysis. (A) Western blot showing Brf1 knockdown efficiency. (B) RT-qPCR measurements of the levels
of indicated tRNAs. RNA levels were normalized to GAPDH mRNA, and the value for the nontreated (NT) Neg siRNA sample was set to 1. (C) Levels of the
indicated interleukins secreted to the culture medium, as determined by ELISA. Results are expressed as corrected OD values as described in Materials and
Methods. (D) RT-qPCRmeasurements of mRNA levels of the indicated interleukins, shown as fold change relaive to GAPDHmRNA. Error bars represent SEM
(n 3).
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Regardless of themechanisms underlying the observed pheno-
types—restriction of cytokine secretion and phagocytosis—it is
clear that Pol III inhibition has a great impact on these important
functions of macrophages. Partial suppression of Pol III may
therefore be worth consideration as an additional treatment in
diseases such as sepsis ormacrophage activation syndrome, where
macrophages play an important role.
To understand how LPS regulate Pol III-dependent transcrip-
tion, we considered downstream signaling. LPS engage the TLR4
receptor and induces various signaling pathways, including those
involvingMAPK, IRF3, andNF-B (22).NF-B is a key transcrip-
tion factor implicated in inflammatory responses but has not
previously been connected to Pol III. Besides its role in the tran-
scription of genes encoding inflammatory cytokines, NF-B also
regulates gene expression related to cell survival, differentiation,
and proliferation. The most extensively studied and most abun-
dant form of NF-B is a heterodimer consisting of p50 and p65.
We therefore focused our attention on the NF-B pathway, in
particular on p65. We found that inhibition of the NF-B path-
way, using either IKK inhibitor or the degradation-resistant su-
perrepressor IkB, partially blocked Pol III induction upon LPS
treatment and that overexpression of p65 protein increased Pol
III-dependent transcription.Moreover, we found that p65 associ-
ates with TFIIIB and binds to tRNA genes upon LPS treatment. It
seems also that p65 binding to tRNA genes is induced not only by
LPS but also by another potent NF-B activator, TNF-. Further-
more, we show that the TAD of p65 is required for Pol III activa-
tion. This is reminiscent of c-Myc, which directly binds to TFIIIB
and also requires its TAD to activate Pol III-dependent transcription
(37). These data strongly support the idea of direct involvement of
p65 in regulation of Pol III activity. However, since blocking the
NF-B pathway caused only partial reduction of LPS-induced tRNA
upregulation, the involvement of other signaling pathways and/or
transcription factors seems likely. Indeed, activationofMAPKsignal-
ing has also been shown to stimulate Pol III transcription directly
(54).
Although ChIP-Seq data sets from different sources are not
reliably comparable, the emerging picture is that p65 associates
with tRNA genes which are already prebound by the Pol III ma-
chinery. Thus, it is unlikely that NF-B serves as a pioneer tran-
scription factor, and its role may rather be related to adjusting Pol
III activity.
It has been shown that infection of macrophages with the par-
asitic protozoan Leishmania leads to decreased expression of cer-
tain Pol III products, including tRNA and 7SL RNA (55, 56).
Downregulation of 7SL RNA suppresses vesicular trafficking and
makes macrophages more susceptible to parasitism. Conversely,
overexpressing 7SL RNA in macrophages protected them against
Leishmania infection (55). This is consistent with our finding that
Pol III activity contributes to immune cell function.
Taken together, our results support the notion that Pol III
activity influencesmacrophage function. Given thatmacrophages
play a crucial role in immunity, our data provide a link between
Pol III-dependent transcription and the innate immune response.
In addition, our study provides novel evidence that the transcrip-
tion factor NF-B is involved in the regulation of Pol III-depen-
dent transcription, in addition to its well-established role in Pol
II-dependent transcription, adding further complexity to the
mechanisms which regulate RNA polymerase III.
FIG 9 Inhibition of RNA polymerase III activity decreases phagocytosis by
macrophages. PMA-differentiated THP-1 cells (n 3) (A to C) and primary
bonemarrow-derivedmacrophages (n 4) (D to G) were treated for 4 h with
DMSO (0.2%) or 100 M RNA polymerase III inhibitor ML-60218, as indi-
cated, and then FBS-opsonized fluorescent latex beads were added. BMDMs
were additionally treatedwith 1g/ml LPS 3hor left untreated before addition
of beads. After 3 h, cells were harvested and analyzed by flow cytometry. (A and
D) Percentages of cells that engulfed at least one bead. (B and E) Percentage of
total mean fluorescent signal of engulfed beads. (C, F, and G) Percentages of
cells that engulfed the indicated numbers of beads. Error bars represent SEM.
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